DEIRDRE CALLAHAN: Open Payments
NPI 1851935894 · ATTLEBORO, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,001 in 104 payments from 7 companies in 2025. Trend: 2023 $2,346 · 2024 $2,560 · 2025 $2,001
Food & beverage: $2,001
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 41 | $842 |
| ABBVIE INC. | 27 | $490 |
| Alkermes, Inc. | 24 | $372 |
| E.R. Squibb & Sons, L.L.C. | 5 | $119 |
| Indivior Inc. | 3 | $98 |
| Neurocrine BioSciences, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: REXULTI, VRAYLAR, ARISTADA, VIVITROL, ABILIFY ASIMTUFII, ABILIFY MAINTENA, COBENFY, SUBLOCADE.
Industry payments across MA — which companies pay providers there.
